Document:

rvlv-ex42_182.htm

Exhibit 4.2

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934

Revolve Group, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Class A common stock, par value $0.001 per share.

The general terms and provisions of our common stock are summarized below. This summary does not purport to be complete and is subject to, and qualified in its entirety by express reference to, the provisions of our certificate of incorporation and bylaws, each of which is included as an exhibit to the Annual Report on Form 10-K to which this description is an Exhibit, and each of which may be amended from time to time. We encourage you to read our certificate of incorporation and bylaws and the applicable provisions of the General Corporation Law of the State of Delaware for additional information.

Our authorized capital stock consists of 1,135,000,000 shares, of which 1,000,000,000 shares are designated Class A common stock, par value $0.001 per share, 125,000,000 shares are designated Class B common stock, par value $0.001 per share, and 10,000,000 shares are designated preferred stock, par value $0.001 per share.

Common Stock 

Voting Rights 

We currently have two classes of authorized common stock, Class A common stock and Class B common stock. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to 10 votes per share. Holders of Class A common stock and Class B common stock vote together as a single class on all matters (including the election of directors) submitted to a vote of stockholders, unless otherwise required by law or our certificate of incorporation. 

Delaware law could require holders of Class A common stock or Class B common stock to vote separately as a single class in the following circumstances: 

	
 
	
•
	
if we were to seek to amend our certificate of incorporation to increase or decrease the par value of a class of our capital stock, then that class would be required to vote separately to approve the proposed amendment; and 

	
 
	
•
	
if we were to seek to amend our certificate of incorporation in a manner that alters or changes the powers, preferences or special rights of a class of our capital stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment. 

Holders of our Class A common stock and Class B common stock are not entitled to cumulative voting in the election of directors, which means that the holders of a majority of the voting power of our Class A common stock and Class B common stock, voting together as a single voting class, are entitled to elect all of the directors standing for election, if they so choose. 

Conversion 

Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. In addition, each share of Class B common stock will convert automatically into one share of Class A common stock upon any transfer, whether or not for value, except for certain transfers described in our certificate of incorporation, including, without limitation, transfers for tax and estate planning purposes, so long as the transferring holder of Class B common stock continues to hold exclusive voting and dispositive power with respect to the shares transferred. 

1

 

All shares of Class B common stock will convert automatically into shares of Class A common stock on the date on which the Class B common stock ceases to represent at least 5% of our outstanding common stock. 

Once converted into a share of Class A common stock, a converted share of Class B common stock will not be reissued. Following the conversion of all outstanding shares of Class B common stock, no further shares of Class B common stock will be issued. 

Dividends 

Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of our Class A common stock and Class B common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. If a dividend is paid in the form of Class A common stock or Class B common stock, then holders of Class A common stock shall receive Class A common stock and holders of Class B common stock shall receive Class B common stock. 

Liquidation 

In the event of our liquidation, dissolution or winding up, holders of our Class A common stock and Class B common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. 

Rights and Preferences 

Except as described above, holders of Class A common stock and Class B common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to Class A common stock or Class B common stock. The rights, preferences and privileges of the holders of Class A common stock and Class B common stock are subject to and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future. 

Fully Paid and Nonassessable

All of our outstanding shares of Class A common stock and Class B common stock are fully paid and nonassessable.

Preferred Stock

Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of Class A common stock or Class B common stock. The issuance of preferred stock could adversely affect the voting power of holders of Class A common stock and Class B common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action.

Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws 

Delaware Law 

We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a publicly held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless: 

2

 

	
 
	
•
	
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; 

	
 
	
•
	
upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or 

	
 
	
•
	
on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. 

	
 
	
•
	
Section 203 defines a business combination to include: 

	
 
	
•
	
any merger or consolidation involving the corporation and the interested stockholder; 

	
 
	
•
	
any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; 

	
 
	
•
	
subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; 

	
 
	
•
	
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and 

	
 
	
•
	
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. 

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. 

Certificate of Incorporation and Bylaws 

Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Among other things, our certificate of incorporation and bylaws: 

	
 
	
•
	
permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in our control; 

	
 
	
•
	
provide that the authorized number of directors may be changed only by resolution of the board of directors, subject to the rights of any holders of preferred stock; 

	
 
	
•
	
provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; 

	
 
	
•
	
require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent; 

	
 
	
•
	
provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate 

3

 

	
 
		
candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and also meet specific requirements as to the form and content of a stockholder’s notice; 

	
 
	
•
	
do not provide for cumulative voting rights (therefore allowing the holders of a plurality of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); 

	
 
	
•
	
provide that special meetings of our stockholders may be called only by the board of directors, the chairman of the board of directors, our chief executive officer or president (in the absence of a chief executive officer);

	
 
	
•
	
provide that stockholders will be permitted to amend certain provisions of our bylaws only upon receiving at least two-thirds of the votes entitled to be cast by holders of all outstanding shares then entitled to vote generally in the election of directors, voting together as a single class; and

	
 
	
•
	
provide that, unless we otherwise consent in writing, a state or federal court located within the State of Delaware shall be the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of the company, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to the company or our stockholders, (3) any action asserting a claim against the company arising pursuant to any provision of the Delaware General Corporation Law, or (4) any action asserting a claim against the company governed by the internal affairs doctrine. 

4uthr_Ex4_2

		
			Exhibit 4.2
		

		
			DESCRIPTION OF THE REGISTRANT’S SECURITIES
		

		
			REGISTERED PURSUANT TO SECTION 12 OF THE
		

		
			SECURITIES EXCHANGE ACT OF 1934
		

		
			United Therapeutics Corporation (“United Therapeutics”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Common Stock, par value $0.01 per share (our “common stock”).
		

		
			DESCRIPTION OF COMMON STOCK
		

		
			The following summary description sets forth some of the general terms and provisions of our common stock. Because this is a summary description, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should refer to the provisions of our amended and restated certificate of incorporation, as amended (our “certificate of incorporation”) and our seventh amended and restated bylaws (our “bylaws”), each of which are filed as exhibits to the Annual Report on Form 10-K to which this description is an exhibit.
		

		
			General
		

		
			Under our certificate of incorporation, United Therapeutics is authorized to issue up to two hundred forty-five million (245,000,000) shares of our common stock and ten million (10,000,000) shares of preferred stock, par value $.01 per share (our “preferred stock”). The shares of our common stock currently outstanding are fully paid and non-assessable. No shares of preferred stock are currently outstanding. Our board of directors has the authority to make, alter, amend and repeal bylaws in any manner not inconsistent with Delaware law.
		

		
			No Preemptive, Redemption or Conversion Rights
		

		
			Our common stock is not redeemable, is not subject to redemption or sinking fund provisions, does not have any conversion rights and is not subject to call. Holders of shares of common stock do not have preemptive rights to acquire newly issued shares.
		

		
			Voting Rights
		

		
			Holders of shares of common stock have one vote per share in all elections of directors and on all other matters submitted to a vote of stockholders of United Therapeutics. Holders of shares of common stock do not have cumulative voting rights.
		

		
			Board of Directors
		

		
			Our board of directors is divided into three classes as nearly equal in number as the then total number of directors constituting the whole board permits. The term of office of each class expires at the third annual meeting of stockholders for election of directors following the election of such class. At each annual meeting of stockholders, directors of the class whose term then expires are elected to hold office for a term expiring as of the third succeeding annual meeting.
		

		
			
		

		
			

		 

		

		
			Our certificate of incorporation provides that the number of directors on our board of directors will be fixed by, or in the manner provided in, our bylaws. Our bylaws establish that the number of directors shall be fixed from time to time by our board of directors but shall not be less than five nor more than twenty.
		

		
			No Action by Stockholder Consent
		

		
			Our certificate of incorporation prohibits action that is required or permitted to be taken at any annual or special meeting of stockholders of United Therapeutics from being taken by the written consent of stockholders without a meeting.
		

		
			Power to Call Special Stockholder Meeting
		

		
			Under Delaware law, a special meeting of stockholders may be called by our board of directors or by any other person authorized to do so in our certificate of incorporation or our bylaws. Our certificate of incorporation provides that special meetings of stockholders may be called only by our board of directors in a resolution approved by a majority of our entire board of directors or by the Chairman of our board of directors, a Vice Chairman of our board of directors or the President of United Therapeutics. At any special meeting of stockholders, only business properly brought before the meeting by or at the direction of the Board of Directors may be conducted.
		

		
			Advance Notice Provisions
		

		
			Our bylaws provide that the proposal of business to be considered by stockholders at the annual meeting of stockholders (other than nominations for the election of directors) may be made only if it is (i) specified in the notice of meeting (or any supplement thereto) given by or at the direction of our board of directors or the persons properly calling the meeting, (ii) otherwise properly brought before the meeting by or at the direction of our board of directors, or (iii) properly brought before the meeting by a stockholder who has complied with the advance notice procedures set forth in our bylaws. Our bylaws also provide that nominations for the election of directors may be made by (i) our board of directors or (ii) any stockholder entitled to vote in such election and who has complied with the advance notice procedures set forth in our bylaws.
		

		
			Proxy Access Nominations
		

		
			Under our bylaws, a stockholder (or a group of up to 20 stockholders) who has held at least 3% of our common stock for three years or more may nominate director nominees constituting up to 20% of the total number of directors then serving on our board, except that the limit shall be 25%
		

		
			
		

		
			

		 

		

		
			if fewer than ten directors are then serving on our board, provided that the stockholder(s) and nominee(s) satisfy the requirements specified in our bylaws.
		

		
			Dividend Rights
		

		
			Subject to the preferences applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive dividends, if any, as and when declared, from time to time, by our board of directors out of funds legally available therefor.
		

		
			Liquidation, Dissolution or Similar Rights
		

		
			Upon dissolution, after satisfaction of the claims of creditors and the payment to any holders of preferred stock of the full preferential amounts to which such holders may be entitled, the remaining assets of United Therapeutics would be distributed to the holders of the common stock ratably in proportion to the number of shares of common stock held by them.
		

		
			Preferred Stock
		

		
			Under our certificate of incorporation, our board of directors has the authority, without further stockholder action, to issue up to 10 million shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series and the designation of such series.
		

		
			Forum Selection Clause
		

		
			Under our bylaws, unless United Therapeutics consents in writing to the selection of an alternative forum, the sole and exclusive forum for making certain types of claims shall be a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware). This provision applies to (a) any derivative action or proceeding brought on behalf of United Therapeutics, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or employee of United Therapeutics to United Therapeutics or United Therapeutics’ stockholders, (c) any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware (the “DGCL”) or our certificate of incorporation or bylaws, (d) any action asserting a claim governed by the internal affairs doctrine, or (e) any action to interpret, apply, enforce or determine the validity of any provision of our certificate of incorporation or bylaws.
		

		
			Anti-Takeover Effects of Provisions of our Certificate of Incorporation, Bylaws, and Delaware Law
		

		
			Various provisions contained in our certificate of incorporation, our bylaws, and Delaware law could delay or discourage some transactions involving an actual or potential change in control of United Therapeutics or its management. For example, under Section 203 of the DGCL, a stockholder holding 15% or more of our outstanding voting stock could not acquire us without consent of our board of directors for at least three years after the date the stockholder first held 15% or more of the voting stock. In addition, our board of directors could, without stockholder approval, implement other anti-takeover defenses, such as a stockholder rights plan.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]